Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts 02111, USA.
Kidney Int. 2011 Feb;79(4):471-7. doi: 10.1038/ki.2010.431. Epub 2010 Oct 27.
Cystatin C is being considered as a replacement for serum creatinine in the estimation of the glomerular filtration rate (GFR); however, its plasma levels might be affected by factors other than the GFR, such as protein intake. We performed a post hoc analysis of the data in the Modification of Diet in Renal Disease study, in which we compared serum creatinine and cystatin C levels in 741 patients with available estimates of protein intake at baseline prior to their randomization to diets containing various amounts of protein, and at 2 years of follow-up in 426 of these patients in whom a cystatin C measurement was available. The 503 patients in study A (GFR 25-55 ml/min per 1.73 m(2)) had been assigned a low (0.58 g/kg per day) or a usual (1.3 g/kg per day) protein intake, and the 238 participants in study B (GFR 13-24 ml/min per 1.73 m(2)) were assigned a very low (0.28 g/kg per day) or the low protein intake. In either study group, lowering the dietary protein intake reduced the change in creatinine, but did not have a significant change in cystatin C. Thus, in patients with moderate-to-severe chronic kidney disease, serum cystatin C unlike serum creatinine was not affected by dietary protein intake independent of changes in GFR. Hence, cystatin C may allow more accurate estimates of GFR than creatinine for patients with reduced protein intake. Further study of other non-GFR determinants of cystatin C is needed before the widespread adoption.
半胱氨酸蛋白酶抑制剂 C 正被视为替代血清肌酐来估算肾小球滤过率(GFR)的一种方法;然而,其血浆水平可能受到除 GFR 以外的因素的影响,如蛋白质摄入量。我们对 Modification of Diet in Renal Disease 研究中的数据进行了事后分析,在这项研究中,我们比较了在随机接受不同蛋白摄入量饮食之前的基线时、以及在 426 名这些患者中的 2 年随访时(其中有可用的半胱氨酸蛋白酶抑制剂 C 测量值)可获得蛋白质摄入量估计值的 741 名患者的血清肌酐和半胱氨酸蛋白酶抑制剂 C 水平。在研究 A(GFR 25-55 ml/min per 1.73 m(2))中的 503 名患者被分配到低蛋白(0.58 g/kg 每天)或通常蛋白(1.3 g/kg 每天)摄入量,而在研究 B(GFR 13-24 ml/min per 1.73 m(2))中的 238 名参与者被分配到极低蛋白(0.28 g/kg 每天)或低蛋白摄入量。在这两项研究中,降低饮食蛋白摄入量均降低了肌酐的变化,但对半胱氨酸蛋白酶抑制剂 C 没有显著影响。因此,在中重度慢性肾脏病患者中,血清半胱氨酸蛋白酶抑制剂 C 与血清肌酐不同,不受 GFR 变化以外的饮食蛋白摄入量的影响。因此,与肌酐相比,半胱氨酸蛋白酶抑制剂 C 可能对半蛋白摄入减少的患者的 GFR 有更准确的估计。在广泛采用之前,需要对半胱氨酸蛋白酶 C 的其他非 GFR 决定因素进行更多的研究。